In the BioHarmony Drug Report Database

"Preview" Icon

Axitinib

Inlyta (axitinib) is a small molecule pharmaceutical. Axitinib was first approved as Inlyta on 2012-01-27. It is used to treat renal cell carcinoma in the USA. It has been approved in Europe to treat renal cell carcinoma. The pharmaceutical is active against vascular endothelial growth factor receptor 2. In addition, it is known to target serine/threonine-protein kinase PLK4. Inlyta’s patents are valid until 2036-11-05 (FDA).

 

Trade Name

 

Inlyta
 

Common Name

 

axitinib
 

ChEMBL ID

 

CHEMBL1289926
 

Indication

 

renal cell carcinoma
 

Drug Class

 

Tyrosine kinase inhibitors

Image (chem structure or protein)

Axitinib structure rendering